Equity
€100 from €286,784 in 2023
Equity fell by 100% in 2 years.
Dr Hendrik Dendooven
Lifetime
5 annual accounts with figures on one time axispeak €146,768 (2025)
€146,768▲ 12.7%
peak €105,737 (2021)
€101,797▲ 7.8%
peak €286,784 (2023)
€100unchanged
€120,790▲ 10.0%
Board2 names since 2021
2 directorsHendrik Willem Dorothy DENDOOVEN and 1 other
Documentsfilings and deeds
29-03-2026124 days before the deadline
2025micro format
Gross margin from €130,172 to €146,768Dividend €101,797
Key points
from the 2025 annual accountsDebts
€120,790 100% of the balance sheet
After one year 0%Within one year 100%
Of this, €120,446 falls due within a year.
Position in the sector
0.1%
Lower solvency than 95% of companies in human health. Sector median 63.0% · 20,749 companies.
Checked score
92
Excellent
Financially stronger than 35% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,179 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025lowest value
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: 0.1%▲ +0.1 percentage points vs 05-2025highest value
07-2025: 0.1%● unchanged vs 06-2025highest value
08-2025: < 0.1%▼ -0.1 percentage points vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Equity €100 (0.1% of total assets)
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 0.96, cash €97,905
Size: total assets €120,890
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 4% of them on solvency, 20% on liquidity, 80% on profitability and 37% on growth.
The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 2,153 companies had the same profile as Dr Hendrik Dendooven has now. Each dot stands for 6 companies, two years later.
96.1%
were still trading
2.2%
stopped another way
1.7%
went bankrupt
The bankruptcy probability of Dr Hendrik Dendooven itself is lower: < 0.1% within 12 months. It rests on far more data about Dr Hendrik Dendooven than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,153 companies, not a prediction for Dr Hendrik Dendooven. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 5% of 20749 sector peers (2025).
NBB · sector comparisonPosition among 20749 sector peers
Solvency
better than 5%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-03-2026, 124 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
124 days early
2024
77 days early
2023
30 days early
2022
28 days early
2021
31 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 58 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 30 June (4 of the last 5 accounts filed within 46 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
06-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0762873326
Registered office moved from Haasrode to Heverlee
New registered office: Verbindingslaan 35, 3001 Heverlee · Previous registered office: Keiberg 31, 3053 Haasrode · Appointment: Charlotte Grootaers (director) · General meeting of 23-05-2023 · Gazette deed
Incorporation
Founder: Hendrik Willem Dorothy DENDOOVEN · Founding capital of €100, 100 shares · Appointment: Hendrik Willem Dorothy DENDOOVEN (director) · published on 05-02-2021 · Gazette deed
First establishment
Verbindingslaan 35, Leuven
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Dr Hendrik Dendooven Leuven | €120,890 | €146,768 | 0.1% | - |
| Dokter Stéphanie De Rechter Herent | €126,450 | €152,591 | 0.1% | - |
| Dr. Margot Stenveld Aarschot | €126,589 | €153,622 | 1.6% | - |
| DR. OLIVIER VANTOMME Rotselaar | €127,988 | €159,785 | 93.7% | - |
| Dr. TH Leuven | €126,936 | €141,593 | 0.1% | - |
| DR. KAREL BUYSE ,HUISARTS Beveren-Kruibeke-Zwijndrecht | €129,078 | €145,778 | 2.3% | - |
| DRTSTULENS Bilzen-Hoeselt | €124,933 | €150,552 | 86.8% | - |
These companies have the same main activity as Dr Hendrik Dendooven: general medical practice (NACE 86210). They are comparable in size and age: total assets between €125,000 and €129,000, founded between 2020 and 2021.
Official details
Source: KBO- Status
- Active since 03-02-2021Normal situation
- Activity
- General medical practiceNACE 86210and 1 other
- Establishment unit
- 2.313.300.9363001 Leuven, since 03-02-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 31-10-2025
Annual accounts 2025
- ≈ €270,000estimated
- €120,890▲ 10.0%
- Filing
- Filed on 29-03-2026, 124 days before the end of the filing period
Insights on Dr Hendrik Dendooven
Dr Hendrik Dendooven files the micro format. That format states no turnover. The gross margin rose from €141,840 in 2021 to €146,768 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Dr Hendrik Dendooven
- What is the company number of Dr Hendrik Dendooven?
- The company number of Dr Hendrik Dendooven is 0762.873.326. The VAT number is the same number with BE in front: BE 0762.873.326.
- Where is Dr Hendrik Dendooven based?
- The registered office is at Verbindingslaan 35, 3001 Leuven.Company details
- What does Dr Hendrik Dendooven do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of Dr Hendrik Dendooven?
- Dr Hendrik Dendooven is a private limited company (BV).
- When was Dr Hendrik Dendooven founded?
- Dr Hendrik Dendooven was founded on 03-02-2021.
- Is Dr Hendrik Dendooven still active?
- Yes, Dr Hendrik Dendooven is an active enterprise in the KBO register.
- What is the turnover of Dr Hendrik Dendooven?
- The turnover in financial year 2025 is ≈ €270,000. This figure is estimated from the gross margin of €146,768 and 30 comparable companies (NACE 86210). It probably lies between €210,000 and €330,000.Financials
- Is Dr Hendrik Dendooven profitable?
- In financial year 2025, Dr Hendrik Dendooven made a profit of €101,797.
- Where can I find the annual accounts of Dr Hendrik Dendooven?
- Dr Hendrik Dendooven filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Dr Hendrik Dendooven due?
- Dr Hendrik Dendooven must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.